Alvotech Prices $152M Public Offering and Private Placement at $3.75/Share
ALVO sits 33% above its 52-week low of $2.94.
Summary
Alvotech has priced its $152 million public offering and concurrent private placement at $3.75 per share, raising significant capital for its biosimilar development and operations.
Key Events · Financing and Capital Events · ALVO
-
Offering Priced
Alvotech priced its public offering of 22.67 million ordinary shares at $3.75 per share, raising approximately $85 million.
-
Concurrent Private Placement
An additional 17.83 million ordinary shares were sold in a private placement at $3.75 per share, generating approximately $67 million.
-
Total Capital Raised
The combined transactions are expected to generate approximately $152 million in gross proceeds for the company.
-
Use of Proceeds
Funds will be used for biosimilar asset development, working capital, general corporate purposes, and potential debt repayment.
Analysis · ALVO · Life Sciences
This filing finalizes the terms and pricing of Alvotech's significant capital raise, which was initially announced yesterday. The company will receive approximately $152 million through a public offering and concurrent private placement, priced at a modest discount to the current market price. This capital is crucial for funding biosimilar development, working capital, and general corporate purposes, providing a substantial financial runway.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALVO was trading at $3.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.94 to $9.94. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.